Lelièvre Damien, Justine Pascale, Christiaens François, Bonaventure Nicole, Coutet Julie, Marrot Laurent, Cotovio José
L'OREAL Research, Life Sciences, 1 Avenue Eugène Schueller, 93 600 Aulnay Sous Bois, France.
Toxicol In Vitro. 2007 Sep;21(6):977-95. doi: 10.1016/j.tiv.2007.04.012. Epub 2007 May 1.
The aim of the study was to investigate the ability of human reconstructed epidermis EpiSkin(LM) to identify the phototoxic potency of topically or systemically applied chemicals (EPA: EpiSkin phototoxicity assay). Three classes, according to their available human phototoxic potential, were evaluated: systemic phototoxic compounds, topical phototoxic chemicals and non-phototoxic compounds. Non-cytotoxic concentrations of chemicals were applied topically or directly added to the underlying culture medium in order to mimic a systemic-like administration. Following treatment, tissues were exposed to non-cytotoxic dose of UVA (50 J cm(-2)). Cell viability and pro-inflammatory mediators (IL-1alpha) were investigated 22 h after UVA exposure. Our results show that the phototoxic potential of chemicals can be determined using cell viability combined with inflammatory mediator measurements (cytokine IL-1alpha) in a 3-D epidermis model. Moreover, the EPA was able to discriminate efficiently between phototoxic and non-phototoxic products. Furthermore, the EPA is sensitive to the administration route in the prediction of the phototoxic potency of the tested chemical. Differences observed between the two routes of administration (topical or systemic-like) may be linked in part to chemicals bioavailability which depends on specific penetration potential, epidermis barrier function and also on keratinocytes absorption/metabolization processes. Results were very promising and showed a very good sensitivity (92.3%) and an excellent specificity (100%) with an overall accuracy of 94.1%. The performances of the EPA showed that the EpiSkin(LM) model is an interesting tool able to integrate decision-making processes to address the question of phototoxicity linked to the application site.
本研究的目的是调查人重组表皮EpiSkin(LM)识别局部或全身应用化学物质光毒性潜力的能力(EPA:EpiSkin光毒性试验)。根据其现有的人体光毒性潜力,评估了三类物质:全身光毒性化合物、局部光毒性化学物质和非光毒性化合物。将无细胞毒性浓度的化学物质局部应用或直接添加到下层培养基中,以模拟全身给药。处理后,将组织暴露于无细胞毒性剂量的紫外线A(50 J cm(-2))。在紫外线A暴露22小时后,研究细胞活力和促炎介质(IL-1α)。我们的结果表明,在三维表皮模型中,结合炎症介质测量(细胞因子IL-1α)使用细胞活力可以确定化学物质的光毒性潜力。此外,EPA能够有效地区分光毒性和非光毒性产品。此外,EPA在预测受试化学物质的光毒性潜力时对给药途径敏感。两种给药途径(局部或类似全身给药)之间观察到的差异可能部分与化学物质的生物利用度有关,生物利用度取决于特定的渗透潜力、表皮屏障功能以及角质形成细胞的吸收/代谢过程。结果非常有前景,显示出非常高的灵敏度(92.3%)和出色的特异性(100%),总体准确率为94.1%。EPA的性能表明,EpiSkin(LM)模型是一个有趣的工具,能够整合决策过程,以解决与应用部位相关的光毒性问题。